🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,265 results for “Gan” Clear

  1. Postoperative adjuvant lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  2. Pre-operative chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension, Brimonidine Tartrate 0.2% w/v Eye Drops., Alphagan 2 mg/ml colirio en solución, IMGN151

    AbbVie Deutschland GmbH & Co. KG

    Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer

    phase 2 small molecule active

    1 trial

  4. Preoperative lanreotide treatment

    The First People's Hospital of Lianyungang

    Acromegaly

    phase 2 small molecule active

    1 trial

  5. Pyrotinib

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Pyrotinib, trastuzumab, paclitaxel-albumin

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  7. QL1706

    The First People's Hospital of Lianyungang

    Local Advanced Esophageal Cancer

    phase 2 small molecule active

    1 trial

  8. QL1706 (Iparomlimab/Tuvonralimab)

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  9. QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  10. Radiation+PD-1 Ab

    The First People's Hospital of Lianyungang

    Proton Therapy

    phase 2 other active

    1 trial

  11. Radiation: Proton Therapy+PD-1 Ab

    The First People's Hospital of Lianyungang

    Proton Therapy

    phase 2 other active

    1 trial

  12. Radiochemoimmunotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  13. Radiotherapy

    The First People's Hospital of Lianyungang

    Cholangiocarcinoma

    phase 2 other terminated

    1 trial

  14. Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor

    The First People's Hospital of Lianyungang

    HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Radiotherapy plus temozolomide

    The First People's Hospital of Lianyungang

    Glioma (Any Grade) in the Brain

    phase 2 small molecule active

    1 trial

  16. Raltitrexed

    The First People's Hospital of Lianyungang

    Inoperable Esophageal Cancer Stage I-III

    phase 2 small molecule active

    1 trial

  17. Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial

    Istituto Gentili S.r.l.

    NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs

    phase 2 other active

    1 trial

  18. Recombinant Human Endostatin Injection

    The First People's Hospital of Lianyungang

    Locally Advanced Squamous Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. Recombinant human endostatin

    The First People's Hospital of Lianyungang

    Stage III Non-small-Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  20. Romiplostim

    The First People's Hospital of Lianyungang

    MDS (Myelodysplastic Syndrome)

    phase 2 small molecule active

    1 trial

  21. Routine Template-based lymphadenectomy

    The First People's Hospital of Lianyungang

    Lymph Node Dissection

    phase 2 other active

    1 trial

  22. Ruxolitinib

    The First People's Hospital of Lianyungang

    Bronchiolitis Obliterans Syndrome

    phase 2 small molecule active

    1 trial

  23. SBRT combined with Nimotuzumab followed by Tislelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

  24. SBRT combined with PD-1 inhibitors and thoracic hyperthermia

    The First People's Hospital of Lianyungang

    Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources